Here is What Hedge Funds Think About Freeline Therapeutics Holdings plc (FRLN)

In this article we will take a look at whether hedge funds think Freeline Therapeutics Holdings plc (NASDAQ:FRLN) is a good investment right now. We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, unconventional data sources, expert networks, and get tips from investment bankers and industry insiders. Sure they sometimes fail miserably, but their consensus stock picks historically outperformed the market after adjusting for known risk factors.

Is Freeline Therapeutics Holdings plc (NASDAQ:FRLN) a healthy stock for your portfolio? Hedge funds were selling. The number of long hedge fund bets dropped by 1 recently. Freeline Therapeutics Holdings plc (NASDAQ:FRLN) was in 5 hedge funds' portfolios at the end of March. The all time high for this statistic is 9. Our calculations also showed that FRLN isn't among the 30 most popular stocks among hedge funds (click for Q1 rankings). There were 6 hedge funds in our database with FRLN positions at the end of the fourth quarter.

Why do we pay any attention at all to hedge fund sentiment? Our research has shown that a select group of hedge fund holdings outperformed the S&P 500 ETFs by 115 percentage points since March 2017 (see the details here). That's why we believe hedge fund sentiment is an extremely useful indicator that investors should pay attention to.

MILLENNIUM MANAGEMENT
MILLENNIUM MANAGEMENT

Israel Englander of Millennium Management

At Insider Monkey, we scour multiple sources to uncover the next great investment idea. For example, an activist hedge fund owns nearly 40% of this $23 biotech stock and is trying to buy the rest for around $50. So, we recommended a long position to our monthly premium newsletter subscribers. We go through lists like the 10 best battery stocks to pick the next Tesla that will deliver a 10x return. Even though we recommend positions in only a tiny fraction of the companies we analyze, we check out as many stocks as we can. We read hedge fund investor letters and listen to stock pitches at hedge fund conferences. You can subscribe to our free daily newsletter on our homepage. Keeping this in mind let's analyze the recent hedge fund action regarding Freeline Therapeutics Holdings plc (NASDAQ:FRLN).

Do Hedge Funds Think FRLN Is A Good Stock To Buy Now?

At Q1's end, a total of 5 of the hedge funds tracked by Insider Monkey were long this stock, a change of -17% from one quarter earlier. The graph below displays the number of hedge funds with bullish position in FRLN over the last 23 quarters. So, let's find out which hedge funds were among the top holders of the stock and which hedge funds were making big moves.